MICHAEL ZADAKIS: Open Payments
NPI 1407548845 · SCOTTSDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,444 in 36 payments from 13 companies in 2025. Trend: 2023 $916 · 2024 $981 · 2025 $1,444
Food & beverage: $1,444
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $369 |
| Alkermes, Inc. | 6 | $315 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $167 |
| ABBVIE INC. | 3 | $148 |
| Janssen Pharmaceuticals, Inc | 5 | $128 |
| Vanda Pharmaceuticals Inc. | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 2 | $66 |
| E.R. Squibb & Sons, L.L.C. | 3 | $63 |
| AngioDynamics, Inc. | 1 | $36 |
| Indivior Inc. | 1 | $31 |
Products named: ABILIFY MAINTENA, ARISTADA, CAPLYTA, VRAYLAR, SPRAVATO, REXULTI, LYBALVI, FANAPT.
Industry payments across AZ — which companies pay providers there.
